Effects of hyperglycemia on glucose metabolism before and after oral glucose ingestion in normal men. 2006

Vincent Rigalleau, and Marie-Christine Beauvieux, and Jean-Louis Gallis, and Henri Gin, and Phillippe Schneiter, and Luc Tappy
Service de Nutrition-Diabétologie, Hôpital Haut-Lévêque, Ave. de Magellan, 33600 Pessac, France. vincent.rigalleau@wanadoo.fr

The plasma glucose excursion may influence the metabolic responses after oral glucose ingestion. Although previous studies addressed the effects of hyperglycemia in conditions of hyperinsulinemia, it has not been evaluated whether the route of glucose administration (oral vs. intravenous) plays a role. Our aim was to determine the effects of moderately controlled hyperglycemia on glucose metabolism before and after oral glucose ingestion. Eight normal men underwent two oral glucose clamps at 6 and 10 mmol/l plasma glucose. Glucose turnover and cycling rates were measured by infusion of [2H7]glucose. The oral glucose load was labeled by D-[6,6-2H2]glucose to monitor exogenous glucose appearance, and respiratory exchanges were measured by indirect calorimetry. Sixty percent of the oral glucose load appeared in the systemic circulation during both the 6 and 10 mmol/l plasma glucose tests, although less endogenous glucose appeared during the 10 mmol/l tests before glucose ingestion (P < 0.05). This inhibitory effect of hyperglycemia was not detectable after oral glucose ingestion, although glucose utilization was increased (+28%, P < 0.05) due to increased nonoxidative glucose disposal [10 vs. 6 mmol/l: +20%, not significant (NS) before oral glucose ingestion; +40%, P < 0.05 after oral glucose ingestion]. Glucose cycling rates were increased by hyperglycemia (+13% before oral glucose ingestion, P < 0.001; +31% after oral glucose ingestion, P < 0.05) and oral glucose ingestion during both the 6 (+10%, P < 0.05) and 10 mmol/l (+26%, P < 0.005) tests. A moderate hyperglycemia inhibits endogenous glucose production and contributes to glucose tolerance by enhancing nonoxidative glucose disposal. Hyperglycemia and oral glucose ingestion both stimulate glucose cycling.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006943 Hyperglycemia Abnormally high BLOOD GLUCOSE level. Postprandial Hyperglycemia,Hyperglycemia, Postprandial,Hyperglycemias,Hyperglycemias, Postprandial,Postprandial Hyperglycemias
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

Vincent Rigalleau, and Marie-Christine Beauvieux, and Jean-Louis Gallis, and Henri Gin, and Phillippe Schneiter, and Luc Tappy
June 2013, The British journal of nutrition,
Vincent Rigalleau, and Marie-Christine Beauvieux, and Jean-Louis Gallis, and Henri Gin, and Phillippe Schneiter, and Luc Tappy
October 1997, Diabetes,
Vincent Rigalleau, and Marie-Christine Beauvieux, and Jean-Louis Gallis, and Henri Gin, and Phillippe Schneiter, and Luc Tappy
August 2012, International journal of sport nutrition and exercise metabolism,
Vincent Rigalleau, and Marie-Christine Beauvieux, and Jean-Louis Gallis, and Henri Gin, and Phillippe Schneiter, and Luc Tappy
March 1978, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Vincent Rigalleau, and Marie-Christine Beauvieux, and Jean-Louis Gallis, and Henri Gin, and Phillippe Schneiter, and Luc Tappy
March 2019, Journal of clinical biochemistry and nutrition,
Vincent Rigalleau, and Marie-Christine Beauvieux, and Jean-Louis Gallis, and Henri Gin, and Phillippe Schneiter, and Luc Tappy
January 1989, Diabete & metabolisme,
Vincent Rigalleau, and Marie-Christine Beauvieux, and Jean-Louis Gallis, and Henri Gin, and Phillippe Schneiter, and Luc Tappy
August 1983, Journal of endocrinological investigation,
Vincent Rigalleau, and Marie-Christine Beauvieux, and Jean-Louis Gallis, and Henri Gin, and Phillippe Schneiter, and Luc Tappy
October 1968, Metabolism: clinical and experimental,
Vincent Rigalleau, and Marie-Christine Beauvieux, and Jean-Louis Gallis, and Henri Gin, and Phillippe Schneiter, and Luc Tappy
January 2017, International journal of sports medicine,
Vincent Rigalleau, and Marie-Christine Beauvieux, and Jean-Louis Gallis, and Henri Gin, and Phillippe Schneiter, and Luc Tappy
December 2018, Diabetes,
Copied contents to your clipboard!